ADBiotech Co., Ltd. (KOSDAQ:179530)

ADBiotech Statistics

Total Valuation

ADBiotech has a market cap or net worth of KRW 61.01 billion. The enterprise value is 66.39 billion.

Market Cap	61.01B
Enterprise Value	66.39B

Important Dates

The last earnings date was Friday, March 27, 2026.

Earnings Date	Mar 27, 2026
Ex-Dividend Date	n/a

Share Statistics

ADBiotech has 19.68 million shares outstanding. The number of shares has increased by 31.45% in one year.

Current Share Class	19.68M
Shares Outstanding	19.68M
Shares Change (YoY)	+31.45%
Shares Change (QoQ)	+14.80%
Owned by Insiders (%)	13.65%
Owned by Institutions (%)	10.65%
Float	8.94M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	4.73
PB Ratio	3.97
P/TBV Ratio	3.99
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-20.09
EV / Sales	5.15
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-3.88

Financial Position

The company has a current ratio of 0.70, with a Debt / Equity ratio of 1.09.

Current Ratio	0.70
Quick Ratio	0.46
Debt / Equity	1.09
Debt / EBITDA	n/a
Debt / FCF	-0.98
Interest Coverage	-1.93

Financial Efficiency

Return on equity (ROE) is -33.04% and return on invested capital (ROIC) is -31.79%.

Return on Equity (ROE)	-33.04%
Return on Assets (ROA)	-6.12%
Return on Invested Capital (ROIC)	-31.79%
Return on Capital Employed (ROCE)	-18.66%
Weighted Average Cost of Capital (WACC)	6.45%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.36
Inventory Turnover	3.32

Taxes

Income Tax	-179.61M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +106.53% in the last 52 weeks. The beta is 0.30, so ADBiotech's price volatility has been lower than the market average.

Beta (5Y)	0.30
52-Week Price Change	+106.53%
50-Day Moving Average	1,882.26
200-Day Moving Average	2,841.59
Relative Strength Index (RSI)	71.93
Average Volume (20 Days)	654,242

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, ADBiotech had revenue of KRW 12.90 billion and -3.30 billion in losses. Loss per share was -275.00.

Revenue	12.90B
Gross Profit	5.15B
Operating Income	-3.50B
Pretax Income	-3.51B
Net Income	-3.30B
EBITDA	-2.54B
EBIT	-3.50B
Loss Per Share	-275.00

Balance Sheet

The company has 11.47 billion in cash and 16.80 billion in debt, with a net cash position of -5.33 billion or -270.96 per share.

Cash & Cash Equivalents	11.47B
Total Debt	16.80B
Net Cash	-5.33B
Net Cash Per Share	-270.96
Equity (Book Value)	15.38B
Book Value Per Share	1,063.73
Working Capital	-8.79B

Cash Flow

In the last 12 months, operating cash flow was -1.32 billion and capital expenditures -15.81 billion, giving a free cash flow of -17.13 billion.

Operating Cash Flow	-1.32B
Capital Expenditures	-15.81B
Depreciation & Amortization	957.02M
Net Borrowing	20.99B
Free Cash Flow	-17.13B
FCF Per Share	-870.44

Margins

Gross margin is 39.91%, with operating and profit margins of -27.14% and -25.62%.

Gross Margin	39.91%
Operating Margin	-27.14%
Pretax Margin	-27.20%
Profit Margin	-25.62%
EBITDA Margin	-19.72%
EBIT Margin	-27.14%
FCF Margin	n/a

Dividends & Yields

ADBiotech does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-31.45%
Shareholder Yield	-31.45%
Earnings Yield	-5.42%
FCF Yield	-28.08%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on May 26, 2021. It was a forward split with a ratio of 3.

Last Split Date	May 26, 2021
Split Type	Forward
Split Ratio	3

Scores

ADBiotech has an Altman Z-Score of -0.41 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-0.41
Piotroski F-Score	4